跳转到主要内容
搜索
海报

Bridging Oncology and Autoimmune Disease: Using QSP to Select T-Cell Engager Doses by CRS Risk and Efficacy

Skip to PDF content

Advance T-Cell Engager Development with QSP Modeling

Explore how Certara’s quantitative systems pharmacology (QSP) expertise can help optimize T-cell engager development, from first-in-human dose selection and step-up dosing strategies to balancing efficacy with cytokine release syndrome (CRS) risk. Learn how mechanistic modeling can support safer, more informed clinical development decisions.

Explore QSP Modeling Services

精选推荐

Leveraging a QSP Platform for Prediction of Clinical Efficacy and Safety Biomarkers in Immuno-Oncology Combination Therapy
Leveraging a QSP Platform for Prediction of Clinical Efficacy and Safety Biomarkers in Immuno-Oncology Combination TherapyPublication

Leveraging a QSP Platform for Prediction of Clinical Efficacy and Safety Biomarkers in Immuno-Oncology Combination Therapy

2nd Model-Informed Drug Development Summit
2nd Model-Informed Drug Development SummitConference

2nd Model-Informed Drug Development Summit

Strategy Starts at Discovery: Using QSP to Choose the Right Indication, the Right Asset, and the Right Path to First-in-Human
Strategy Starts at Discovery: Using QSP to Choose the Right Indication, the Right Asset, and the Right Path to First-in-HumanOn-Demand Webinar

Strategy Starts at Discovery: Using QSP to Choose the Right Indication, the Right Asset, and the Right Path to First-in-Human

沪ICP备2022021526号
Powered by Translations.com GlobalLink Web Software